CATALYST PHARMACEUTICALS, INC.

Key metrics

Financial performance

Net profit margin expanded from -6800.7% to 36.4% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,337 filings)

Recent press releases

• Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results2026-05-11

  _Delivered Q1 2026 Total Revenues_ _of $149.4 Million_

• Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.2026-05-07

  _As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035_

• Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast2026-05-07

  Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

• Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 20262026-04-28

  The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event.

• Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference2026-03-06

  “The MDA meeting is a key opportunity to highlight the expanding real‑world evidence shaping care for the Duchenne community,” said Will Andrews, MD, Chief Medical Officer of Catalyst. “Through our poster presentations and our sponsored symposium on long‑term evidence generation, we’re contributing clinical insights that help clarify AGAMREE®’s profile and its role in patient care. Our commitment is to advance rigorous, meaningful research that moves the field forward for patients and their families.”

Similar companies

The largest companies sharing CATALYST PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).